A research team from the University of Barcelona (UB), led by Dr Christian Gri\u00f1\u00e1n, professor at the Faculty of Pharmacy and Food Sciences, has developed a new family of compounds with potential for the treatment of neurodegenerative diseases such as Alzheimer\u2019s, Parkinson\u2019s and Huntington\u2019s disease.<\/p>\n
The technology, available for licensing through the Bosch i Gimpera Foundation (FBG), is based on a novel therapeutic strategy targeting epigenetic mechanisms involved in brain function.<\/p>\n
Neurodegenerative diseases represent one of the major global health challenges, driven both by population ageing and their significant social and economic impact. Despite advances in research, current treatments are not curative and, in many cases, only help to alleviate symptoms. This context highlights the need to develop new approaches capable of targeting the underlying causes of the disease and modifying its progression.<\/p>\n
The technology developed by UB focuses on inhibiting the FTO protein, an enzyme involved in the epigenetic regulation of RNA and in key processes such as memory, neuronal plasticity and neurogenesis. Alterations in this mechanism have been associated with neuronal degeneration and cognitive decline. Unlike other compounds developed to date, the new candidates show a strong ability to reach the brain, a key requirement for treating central nervous system diseases.<\/p>\n
Preliminary studies have shown that these compounds exert neuroprotective effects in relevant experimental models and contribute to improving memory and cognitive functions. In addition, the lead compound shows improved pharmacological properties compared to existing approaches, with higher potency and a more suitable profile for drug development.<\/p>\n
The technology is currently at an advanced stage of preclinical research, following an optimisation process that has enabled the identification of the most promising candidates. The next steps will focus on validating efficacy and safety in more advanced studies, as well as defining the strategy for clinical development and eventual market entry.<\/p>\n
With an innovative mechanism of action and promising results, this technology represents a valuable opportunity for pharmaceutical and biotechnology companies interested in developing new therapies for neurodegenerative diseases. The research team is seeking to establish licensing agreements, while also considering collaborations to jointly advance its development.<\/p>\n